Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK1399686
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
GSK1399686 is an orally administered anti-inflammatory macrolide conjugate compound developed by GSK. It was investigated primarily for the treatment of ulcerative colitis and other inflammatory bowel diseases. The drug acts as a small molecule and functions as a 50S ribosomal subunit inhibitor, targeting bacterial protein synthesis pathways. Clinical trials reached up to Phase 2 for ulcerative colitis, but there is no evidence of approval or ongoing development beyond these studies[2][5][6].
- Brand names
- ASACOL
- Other names
- 1399686GSK-1399686GSK1399686GSK 1399686
02
Targets
Bacterial 50S ribosomal subunit
Beyond the preview
Go deeper on GSK1399686.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK1399686.